8-K: Intelligent Bio Solutions Reports Mixed FY25 Results

Intelligent Bio Solutions Inc. announced its fiscal 2025 fourth quarter and full-year results, highlighting progress on U.S. market expansion and revenue growth in Q4, despite a full-year net loss increase and significant cash reduction.

Summary

• Intelligent Bio Solutions Inc. reported fiscal fourth quarter 2025 revenue of $843,884, a 16% increase year-on-year and quarter-on-quarter.
• Full fiscal year 2025 revenue was $3,052,532, a slight decrease from $3,111,781 in fiscal year 2024.
• Net loss for the full fiscal year 2025 increased to $(10,604,886) from $(10,190,932) in fiscal year 2024.
• Cash and cash equivalents significantly decreased to $1,019,909 as of June 30, 2025, from $6,304,098 as of June 30, 2024.
• The company advanced efforts to secure U.S. FDA 510(k) clearance for its opiate test system, submitting a comprehensive dataset.
• Cartridge sales, the highest-margin revenue stream, increased 9% quarter-on-quarter and 24% year-on-year for Q4, and 14% year-on-year for the full fiscal year.
• Secured 115 new accounts during the year, bringing the total active customer base to over 450 across 24 countries with 18 distribution partners.
• Implemented operational efficiencies, including product enhancements, manufacturing improvements, systems upgrades, and localized strategies.
• Strengthened intellectual property with the addition of a sixth U.S. patent.

Sentiment

Score: 4

Explanation: While the company shows strong operational progress in Q4, including revenue growth and FDA pathway advancement, the full fiscal year financial results are concerning. The significant increase in net loss and drastic reduction in cash and total assets indicate a deteriorating financial position and high cash burn, raising questions about long-term sustainability without further capital.

Positives

• Fiscal Q4 2025 revenue increased by 16% year-on-year and quarter-on-quarter, reaching $843,884.
• Cartridge sales, a high-margin revenue stream, showed strong growth, increasing 9% quarter-on-quarter and 24% year-on-year for Q4, and 14% year-on-year for the full fiscal year.
• Secured 115 new accounts during the year, expanding the active customer base to over 450 across 24 countries.
• Progressed significantly towards U.S. FDA 510(k) clearance for its opiate test system, with a comprehensive data submission.
• Expanded regulatory efforts beyond the U.S. in Canada, Indonesia, and the Philippines.
• Implemented operational efficiencies, including product enhancements, manufacturing improvements, and systems upgrades, aimed at improving gross margins and reducing net loss.
• Completed multilingual upgrades to the Intelligent Fingerprinting Drug Screening System and launched regionally localized websites.
• Strengthened intellectual property portfolio with the addition of a sixth U.S. patent.
• Selling, general and administrative expenses decreased to $(8,883,917) in FY25 from $(9,258,496) in FY24.

Negatives

• Full fiscal year 2025 revenue decreased slightly to $3,052,532 from $3,111,781 in fiscal year 2024.
• Net loss for the full fiscal year 2025 increased to $(10,604,886) from $(10,190,932) in fiscal year 2024.
• Cash and cash equivalents significantly declined to $1,019,909 as of June 30, 2025, from $6,304,098 as of June 30, 2024, indicating substantial cash burn.
• Total assets decreased to $8,249,786 from $13,778,863 year-over-year.
• Accumulated deficit increased to $(62,533,065) as of June 30, 2025, from $(51,964,332) as of June 30, 2024.
• Development and regulatory approval expenses increased to $(2,396,513) in FY25 from $(1,673,806) in FY24.
• Incurred an impairment of long-lived assets of $(220,062) in FY25.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially.
• Ability to successfully develop and commercialize drug and diagnostic tests is not guaranteed.
• Realizing commercial benefit from partnerships and collaborations is subject to uncertainties.
• Securing regulatory approvals, such as FDA 510(k) clearance, is not assured and may face unforeseen challenges.

Future Outlook

The company is focused on accelerating growth, advancing operational excellence, and expanding beyond Forensic Use Only settings in the U.S. The FDA regulatory pathway remains on track, with a commitment to achieving FDA clearance to enter the U.S. drug screening market. The company expects the accelerated pace of new active account growth to continue into the future and plans to complete the implementation of a new accounting system for its subsidiary by the third fiscal quarter of FY2025-2026.

Management Comments

• Harry Simeonidis, President and CEO: "Fiscal 2025 was a pivotal year for our business as we continued to lay the foundation for global growth... We delivered sequential growth over fiscal quarters three and two, driven by increased cartridge revenue, improved operational discipline, and growing international momentum. As we enter fiscal 2026, we're focused on three strategic priorities: further accelerating growth, advancing operational excellence, and expanding beyond Forensic Use Only settings in the U.S. Our FDA regulatory pathway remains on track, and we are committed to achieving FDA clearance to expand into the U.S., the world's largest drug screening market, and deliver our non-invasive solution to more organizations seeking fast, dignified, and reliable testing alternatives."
• Spiro Sakiris, Chief Financial Officer: "We've achieved an enormous amount over fiscal 2025, delivering quarter-on-quarter growth, with accelerated momentum in the second half... This consistent performance reflects the growing traction of our testing solutions in key markets and gives us confidence in our trajectory as we move into fiscal 2026."

Industry Context

Intelligent Bio Solutions operates in the medical technology sector, specifically focusing on rapid, non-invasive drug testing solutions. The company's emphasis on securing FDA clearance for broader U.S. market access beyond 'Forensic Use Only' settings positions it to compete in the significant U.S. drug screening market. Its fingerprint sweat-based technology offers a hygienic and cost-effective alternative to traditional methods, aligning with a growing industry trend towards less invasive and more efficient testing. International expansion and increasing customer accounts suggest a strong global demand for such solutions, particularly in safety-critical industries.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential for dilution if a capital raise occurs; share price likely to be volatile based on FDA progress and financial performance; long-term value dependent on successful U.S. market expansion and profitability.
• Employees: Continued investment in operations and regulatory efforts suggests stability, but financial losses could impact future hiring or compensation.
• Customers: Expansion of product offerings and localized support enhances service; FDA clearance would broaden access to the technology in the U.S.
• Suppliers: Ongoing operations and potential growth could lead to increased demand for supplies.
• Creditors: Deteriorating cash position and increasing accumulated deficit may raise concerns about the company's ability to meet future obligations without additional funding.

Next Steps

• Further accelerating growth in fiscal 2026.
• Advancing operational excellence.
• Expanding beyond Forensic Use Only settings in the U.S. market.
• Achieving FDA clearance for its opiate test system.
• Continuing regulatory expansion efforts in Canada, Indonesia, and the Philippines.
• Continuing the accelerated pace of new active account growth.
• Completing the implementation of a new accounting system for Intelligent Fingerprinting Limited by the third fiscal quarter of FY2025-2026.

Key Dates

Recommendation

The company presents a mixed bag of results. While there's clear strategic progress, particularly with the FDA clearance pathway and strong Q4 operational growth in cartridge sales and new accounts, the full fiscal year financial performance is concerning. The significant cash burn, increased net loss, and low cash balance ($1 million) indicate a precarious financial position that will likely necessitate a capital raise. For a seasoned investor, the potential upside from FDA clearance and U.S. market entry is substantial, but the current financial instability and high execution risk warrant caution. A 'hold' recommendation allows investors to monitor the critical FDA approval process and the company's ability to manage its cash flow, without committing further capital into a financially challenged entity, or exiting before potential transformative news.

Keywords

Drug Screening, Medical Technology, FDA Clearance, Fingerprint Testing, Non-invasive Testing, Biotechnology, Diagnostic Tests, Forensic Use, Workplace Drug Testing, INBS